Previous 10 | Next 10 |
2023-09-26 16:16:34 ET More on Galecto Seeking Alpha’s Quant Rating on Galecto Historical earnings data for Galecto Financial information for Galecto Galecto to drop lung disease drug after Phase 2 setback For further details see: Galecto r...
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, ...
2023-09-14 08:15:00 ET Summary Galecto Biotech's stock has plummeted 75% due to increased rates of adverse events in its idiopathic pulmonary fibrosis (IPF) trial. Galecto's synthetic, small molecule approach to galectin-3 inhibition may be causing poor tolerability and negative c...
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President and Chief Executiv...
2023-08-15 13:14:27 ET Gainers: Delcath Systems ( DCTH ) +96% . Sacks Parente Golf ( SPGC ) +95% . Novo Integrated Sciences ( NVOS ) +61% . T2 Biosystems ( TTOO ) +45% . Siyata Mobile ( SYTA ) +36% . Grove Collaborative Holdi...
2023-08-15 10:17:36 ET Gainers: Delcath Systems ( DCTH ) +90% . Pharvaris ( PHVS ) +22% . ENDRA Life Sciences ( NDRA ) +14% . NeurAxis ( NRXS ) +12% . SomaLogic ( SLGC ) +12% . Losers: Design Therapeutics ( DSGN ) -6...
2023-08-15 08:30:39 ET Altisource Asset Management Corporation AAMC -66% after Q2 earning release . Galecto ( GLTO ) -65% announces topline results from phase 2b GALACTIC-1 trial of GB0139 for the treatment of Idiopathic pulmonary fibrosis. Design Therapeutics ...
2023-08-15 08:02:50 ET More on Galecto Galecto an outperform at Oppenheimer on fibrosis assets catalysts Galecto stock rises 12% as GB1211 shows efficacy in liver disease patients in trial Galecto’s GB1211 to be studied for phase 2 trial in combination with pe...
BOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments for fibrosis and cancer, today announced topline results from its Phase 2b GALACTIC-1 trial evaluatin...
2023-07-31 17:13:57 ET Galecto press release ( NASDAQ: GLTO ): Q2 GAAP EPS of -$0.41. Cash, cash equivalents, and investments as of June 30, 2023 were approximately $52.1 million. For further details see: Galecto GAAP EPS of -$0.41
News, Short Squeeze, Breakout and More Instantly...
Galecto Inc. Company Name:
GLTO Stock Symbol:
NASDAQ Market:
BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that the first patient has been enrolled in an investigator-initiated Phase 2 trial to evaluate GB1...
Morgan Advanced Materials Plc (MCRUF) is expected to report for Q4 2023 Security Federal Corp (SFDL) is expected to report for Q1 2024 Bank of the James Financial Group Inc. (BOTJ) is expected to report for Q1 2024 OMV AG (OMVJF) is expected to report $1.91 for Q1 2024 Pola Orbis ...